Jane Street Group LLC lifted its position in Inari Medical, Inc. (NASDAQ:NARI – Free Report) by 32.4% in the 3rd quarter, according to the company in its most recent filing with the SEC.

https://www.tipranks.com/news/the-fly/biontech-to-pay-791-5m-in-settlement-agreement-with-the-nih Truist analyst Richard Newitter raised the firm’s price target on ...

Truist analyst Richard Newitter raised the firm’s price target on Inari Medical (NARI) to $63 from $50 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in ...

Analyst Price Forecast Suggests 16.57% Upside As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share. The forecasts range from a low of $50.50 to a high of $90.30.

Analysts' ratings for Inari Medical (NASDAQ:NARI) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table encapsulates their recent ratings, offering a ...

Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy for the treatment of deep vein thrombosis and pulmonary ...

When deputies arrived, they learned that a vehicle carrying medical supplies was being delivered to a hospital in Macon. According to officials, the supplies are Technetinium 99M, a radioactive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...